PARIS--(BUSINESS WIRE)-- Continued innovation and therapeutic progress - In the human healthcare market, the survey revealed that the French life science industry is sustainably pursuing its growth; in 2009, 11 products were on the market and 84 were in clinical development (including 10 in Phase III and 4 in the registration phase). The 20% increase in the number of clinical-phase products (up from 55 in 2008 to 66 in 2009, when only considering the 54 companies surveyed both this year and last year) confirms the maturation of France’s portfolio of life science companies.
